| 3201 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
62 |
| 3202 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
63 |
| 3203 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
71 |
| 3204 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3205 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
33 |
| 3206 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
3 |
| 3207 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
65 |
| 3208 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
16 |
| 3209 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
66 |
| 3210 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3211 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
71 |
| 3212 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
62 |
| 3213 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
48 |
| 3214 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
62 |
| 3215 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
48 |
| 3216 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
73 |
| 3217 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
69 |
| 3218 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
79 |
| 3219 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
54 |
| 3220 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
44 |
| 3221 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
63 |
| 3222 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
56 |
| 3223 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
65 |
| 3224 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3225 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
65 |
| 3226 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3227 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
65 |
| 3228 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
70 |
| 3229 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
66 |
| 3230 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
88 |
| 3231 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
67 |
| 3232 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
52 |
| 3233 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
57 |
| 3234 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
62 |
| 3235 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
36 |
| 3236 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
61 |
| 3237 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
11 |
| 3238 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
61 |
| 3239 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome – Raeb2
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
62 |
| 3240 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome Rc
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
3 |
| 3241 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome With Excess Blasts 1
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
59 |
| 3242 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome With Excess Blasts 2
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
67 |
| 3243 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome With Fibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3244 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
58 |
| 3245 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
69 |
| 3246 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
57 |
| 3247 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3248 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
73 |
| 3249 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
67 |
| 3250 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
66 |
| 3251 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
69 |
| 3252 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
60 |
| 3253 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
69 |
| 3254 |
Apheresis |
Allogeneic
|
Myelofibrosis Post Essential Thrombocythemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3255 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
58 |
| 3256 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3257 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
73 |
| 3258 |
Apheresis |
Autologous
|
Myeloma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
54 |
| 3259 |
Apheresis |
Allogeneic
|
Myeloma Multiplex
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
31 |
| 3260 |
Apheresis |
Allogeneic
|
Myeloproliferative Neoplasms With Acute Myeloid Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
59 |
| 3261 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
50 |
| 3262 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
37 |
| 3263 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3264 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
59 |
| 3265 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
21 |
| 3266 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
38 |
| 3267 |
Apheresis |
Autologous
|
Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
31 |
| 3268 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
73 |
| 3269 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
61 |
| 3270 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
53 |
| 3271 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
18 |
| 3272 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
28 |
| 3273 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
55 |
| 3274 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
59 |
| 3275 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
52 |
| 3276 |
Apheresis |
Allogeneic
|
Osteomyelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
59 |
| 3277 |
Apheresis |
Allogeneic
|
Osteomyelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
59 |
| 3278 |
Apheresis |
Allogeneic
|
Other Immune System
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
46 |
| 3279 |
Apheresis |
Allogeneic
|
Other Malignancy
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
72 |
| 3280 |
Apheresis |
Allogeneic
|
Peripheral T-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
32 |
| 3281 |
Apheresis |
Allogeneic
|
Plasma Cell Disorder
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
56 |
| 3282 |
Apheresis |
Allogeneic
|
Plasma Cell Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
58 |
| 3283 |
Apheresis |
Allogeneic
|
Post-Essential Thrombocythemia-Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
64 |
| 3284 |
Apheresis |
Allogeneic
|
Post–Polycythemia Vera Myelofibrosis (Post-Pv Mf)
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
48 |
| 3285 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
65 |
| 3286 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
65 |
| 3287 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
58 |
| 3288 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
39 |
| 3289 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
67 |
| 3290 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
37 |
| 3291 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
69 |
| 3292 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
62 |
| 3293 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
66 |
| 3294 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
70 |
| 3295 |
Apheresis |
Allogeneic
|
Primary Refractory T-Cell Lymphoma
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
55 |
| 3296 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
58 |
| 3297 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2022
|
Standard Therapy
|
Germany
|
51 |
| 3298 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
53 |
| 3299 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
45 |
| 3300 |
Apheresis |
Allogeneic
|
Severe Combined Immunodeficiency
|
Hematology
|
2022
|
Standard Therapy
|
Poland
|
3 |